Hepion net loss widens to $1.25 million in Q2 2026; revenue flat at no revenue

Reuters2026/08/13 10:59

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hepion posted a net loss of USD 1.25 million for the quarter ended June 30, 2026, widening from USD 1.04 million.
Operating loss narrowed to USD 1.21 million from USD 1.75 million, on lower operating expenses of USD 1.21 million.
General and administrative costs rose to USD 1.16 million from USD 919,488, while research and development spending fell to USD 50,918 from USD 423,277.
No revenue was reported, while a USD 42,989 warrant fair-value loss replaced a USD 698,073 gain a year earlier.
Strategy shifted toward diagnostics, including a Cirna Diagnostics license with USD 70,000 paid upfront and potential milestones up to USD 6.85 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hepion Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037562), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hepion net loss widens to $1.25 million in Q2 2026; revenue flat at no revenue

You may also like

Crypto prices